S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55

Sarepta Therapeutics Price Target, Predictions & Analyst Ratings

-4.98 (-7.00%)
(As of 01/18/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.87 million shs
Average Volume
1.57 million shs
Market Capitalization
$5.76 billion
P/E Ratio
Dividend Yield

Sarepta Therapeutics (NASDAQ:SRPT) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Based on 15 Analyst Ratings

Analyst Price Target Consensus

88.82% Upside

High PT$160.00
Average PT$124.85
Low PT$90.00
1/19/21 to 1/19/22
1 Month Ago
12/20/20 to 12/20/21
3 Months Ago
10/21/20 to 10/21/21
1 Year Ago
1/20/20 to 1/19/21
Consensus Rating
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
11 Buy rating(s)
13 Buy rating(s)
11 Buy rating(s)
15 Buy rating(s)
4 Hold rating(s)
7 Hold rating(s)
9 Hold rating(s)
7 Hold rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$124.85$124.47$131.88$164.41
Price Target Upside88.82% Upside26.23% Upside21.97% Upside8.86% Upside
Get Sarepta Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.

Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Sarepta Therapeutics (NASDAQ:SRPT) vs. Its Competitors

TypeSarepta TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
Consensus RatingBuyBuyBuy
Price Target Upside88.82% Upside264.06% Upside12.73% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
Community Rating
Outperform Votes
Underperform Votes
Avg. Outperform Votes
Avg. Underperform Votes
Avg. Outperform Votes
Avg. Underperform Votes

Sarepta Therapeutics (NASDAQ:SRPT) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/18/2022Morgan Stanley
Boost Price TargetEqual Weight$90.00 ➝ $92.00+36.80%
1/11/2022Needham & Company LLC
Gil Blum
Reiterated RatingBuy$150.00+101.94%
UpgradeMarket Perform ➝ Outperform$125.00+45.32%
11/5/2021JPMorgan Chase & Co.
Anupam Rama
UpgradeNeutral ➝ Overweight$88.00 ➝ $130.00+49.48%
11/4/2021Cantor Fitzgerald
Boost Price TargetOverweight$128.00 ➝ $140.00+61.79%
11/4/2021Royal Bank of Canada
Lower Price TargetOutperform$148.00 ➝ $145.00+67.57%
10/15/2021Berenberg Bank
Zhiqiang Shu
Reiterated RatingHold$90.00+6.03%
10/12/2021Credit Suisse Group
Boost Price TargetNeutral$75.00 ➝ $100.00+9.54%
10/12/2021SVB Leerink
Reiterated RatingBuy
10/12/2021BTIG Research
Boost Price TargetBuy$110.00 ➝ $125.00+36.93%
10/7/2021Robert W. Baird
Initiated CoverageBuy$110.00+13.08%
UpgradeNeutral ➝ Buy
4/16/2021William Blair
Reiterated RatingBuy
3/2/2021Piper Sandler
Lower Price TargetNeutral$140.00 ➝ $130.00+49.37%
Boost Price TargetBuy$158.00 ➝ $160.00+87.68%
1/12/2021Smith Barney Citigroup
DowngradeBuy ➝ Neutral
1/11/2021UBS Group
DowngradeBuy ➝ Neutral
Lower Price TargetOutperform$213.00 ➝ $114.00-32.52%
Lower Price TargetPositive ➝ Overweight$192.00 ➝ $125.00-26.01%
1/8/2021Raymond James
DowngradeOutperform ➝ Market Perform
Boost Price TargetBuy$177.00 ➝ $190.00+37.18%
8/31/2020HC Wainwright
Debjit Chattopadhyay
Lower Price TargetBuy$260.00 ➝ $221.00+49.87%
8/21/2020Bank of America
Tazeen Ahmad
Lower Price TargetBuy$190.00 ➝ $189.00+34.07%
Reiterated RatingBuy$230.00+62.83%
2/27/2020JMP Securities
Lower Price TargetOutperform$280.00 ➝ $217.00+90.97%
2/25/2020Nomura Securities
Reiterated RatingBuy$230.00+92.36%
12/24/2019The Goldman Sachs Group
Salveen Richter
Reiterated RatingBuy$180.00+34.03%
12/23/2019Piper Jaffray Companies
Danielle Brill
Reiterated RatingBuy$210.00+54.89%
12/13/2019Janney Montgomery Scott
Boost Price TargetBuy$160.00 ➝ $175.00+74.18%
8/8/2019Evercore ISI
Reiterated RatingBuy$200.00+49.31%
3/12/2019BMO Capital Markets
Initiated CoverageOutperform
(Data available from 1/19/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sarepta Therapeutics (NASDAQ:SRPT) Analyst Ratings Frequently Asked Questions

What is Sarepta Therapeutics's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for Sarepta Therapeutics stock is Buy based on the current 4 hold ratings and 11 buy ratings for SRPT. The average twelve-month price target for Sarepta Therapeutics is $124.85 with a high price target of $160.00 and a low price target of $90.00. Learn more on SRPT's analyst rating history

Do Wall Street analysts like Sarepta Therapeutics more than its competitors?

Analysts like Sarepta Therapeutics stock more than the stock of other Medical companies. The consensus rating score for Sarepta Therapeutics is 2.73 while the average consensus rating score for medical companies is 2.72. Learn more on how SRPT compares to other companies

Do MarketBeat users like Sarepta Therapeutics more than its competitors?

MarketBeat users like Sarepta Therapeutics stock more than the stock of other Medical companies. 77.08% of MarketBeat users gave Sarepta Therapeutics an outperform vote while medical companies recieve an average of 67.57% outperform votes by MarketBeat users.

Is Sarepta Therapeutics being upgraded by Wall Street analysts?

Over the previous 90 days, Sarepta Therapeutics's stock had 2 upgrades by analysts.

Does Sarepta Therapeutics's stock price have much upside?

According to analysts, Sarepta Therapeutics's stock has a predicted upside of 46.11% based on their 12-month price targets.

What analysts cover Sarepta Therapeutics?

Sarepta Therapeutics has been rated by Cantor Fitzgerald, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer, and Royal Bank of Canada in the past 90 days.

This page was last updated on 1/19/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.